ReviewCurrent atherosclerosis reports2010
Insights into atherosclerosis using nanotechnology.
Review in Current atherosclerosis reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- Anti-cancer Properties of Epigallocatechin-3-gallate (EGCG) and its Signaling Pathways.Current medicinal chemistry · 2025Review
- Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis.Drug delivery · 2021Review
- Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis.Journal of visualized experiments : JoVE · 2017Article
- Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Detection and treatment of atherosclerosis using nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets.Future medicinal chemistry · 2016Review
- Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis.PloS one · 2016Article
- Nanotechnology in diagnosis and treatment of coronary artery disease.Nanomedicine (London, England) · 2016Review
- Nanoengineering of therapeutics for retinal vascular disease.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015Review
- Molecular imaging of retinal disease.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Review
- Inflammation in atherosclerosis: a cause or a result of vascular disorders?Journal of cellular and molecular medicine · 2012Review
- New technologies personalize diagnostics and therapeutics.Current atherosclerosis reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A developing forefront in vascular disease research is the application of nanotechnology, the engineering of devices at the molecular scale, for diagnostic and therapeutic applications in atherosclerosis. Promising research in this field over the past decade has resulted in the preclinical validation of nanoscale devices that target cellular and molecular components of the atherosclerotic plaque, including one of its prominent cell types, the macrophage. Nanoscale contrast agents targeting constituents of plaque biology have been adapted for application in multiple imaging modalities, leading toward more detailed diagnostic readouts, whereas nanoscale drug delivery devices can be tailored for site-specific therapeutic activity. This review highlights recent progress in utilizing nanotechnology for the clinical management of atherosclerosis, drawing upon recent preclinical studies relevant to diagnosis and treatment of the plaque and promising future applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.